Pharmaceuticals

A Chinese AI innovator and a new European biotech just sealed a massive deal. It’s a blueprint for the future of medicine, where technology and strategy unite for patients.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

Merck's positive Phase 3 results for tulisokibart signal a new era for UC care, targeting both fibrosis and inflammation in a potential first-in-class win.

Sanofi taps AI-native biotech expert Paulo Fontoura to lead its global R&D, a high-stakes move to accelerate drug discovery after recent pipeline disappointments.

A new index reveals pharma's $8B ad spend fails to buy AI visibility. Eli Lilly and Novo Nordisk lead as AI follows patient research, not TV spots.

With no approved drugs for the Bundibugyo Ebola outbreak, 101 Therapeutics releases un-reviewed data, forcing a global health showdown between speed and safety.

Straive's acquisition of NextGen Invent isn't just another deal; it's a strategic strike to dominate the AI operationalization market. Here's why.

At BIO 2026, Fapon Group unveils a novel strategy combining T-cell engagers and in vivo CAR-T to target complex diseases. What does this mean for the future?

As global supply chains shift, a conference in Montreal highlights a crucial trade realignment. But are Canadian firms ready to seize the massive EU opportunity?

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

Beyond deep discounts, COSRX's Amazon Prime Day offensive reveals a masterclass in digital strategy, leveraging viral products to dominate Europe's beauty market.

A strategic pharma alliance scores a major win in Japan's lucrative neurology market, signaling a new competitive front and hope for thousands of patients.

South Korea's Wellness Innercell targets Indonesia's booming wellness market. Its Surabaya-first strategy reveals a calculated blueprint for navigating Southeast Asia.

A prestigious award for its ASD therapy Speragen puts Korean biotech Astrogen in the spotlight. Now, the firm faces the gauntlet of regulatory approval and market entry.

The biotech firm's revenue plummeted as losses soared. But behind the numbers is a calculated pivot to cancer therapy, fueled by a Nasdaq debut and new cash.

AbbVie's latest dividend increase isn't just good news for investors; it's a window into the pharma giant's strategy for navigating future challenges.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

Life science labs are eagerly exploring AI, but new data reveals a major roadblock: a fragmented digital landscape that keeps true innovation just out of reach.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?